TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11346806

Group type: EXPERIMENTAL
Intervention: Succimer (lead chelator), administered orally in up to three 26-day courses
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Succimer
Number of subjects: 780
Study: 9812581

Group type: EXPERIMENTAL
Intervention: Breakfast with carbohydrate as major composition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Breakfast with higher lipid and protein composition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Breakfast with reasonable calorie allocation
Number of subjects: 30
Study: 7951008

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 3300121

Group type: EXPERIMENTAL
Intervention: Cefuroxime (two-dose peroperative regimen)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Ampicillin and metronidazole (combined peroperative and postoperative for 4 days)
Number of subjects: 418
Study: 30120478

Group type: EXPERIMENTAL
Intervention: Triple combination pill (20 mg telmisartan, 2.5 mg amlodipine, 12.5 mg chlorthalidone)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Triple combination pill
Number of subjects: 700
Study: 29231403

Group type: EXPERIMENTAL
Intervention: Acupuncture based on meridian differentiation, with main acupoints including Neiguan (PC 6), Shuigou (GV 26), Sanyinjiao (SP 6), Fengchi (GB 20), Lianquan (CV 23), Jialianquan (Extra), Jinjin (EX-HN 12), Yuye (EX-HN 13), retained for 30 min, once daily, 5 treatments a week for 6 weeks.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional medication and rehabilitation training with control acupuncture points selected 5 cm lateral to the main acupoints, retained for 30 min, once daily, 5 treatments a week for 6 weeks.
Number of subjects: 130
Study: 24286245

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring microintervention (90 minutes)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control intervention (details not specified)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No-intervention condition
Number of subjects: 92
Study: 23414648

Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 3838

Group type: COMPARATOR
Intervention: BE
Number of subjects: 3838
Study: 20096399

Group type: EXPERIMENTAL
Intervention: Cognitive avoidance
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Fear of emotion
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Cognitive avoidance and GAD symptoms
Number of subjects: 1220
Study: 18202581

Group type: EXPERIMENTAL
Intervention: Exercise intervention (moderate/vigorous-intensity aerobic activity for 60 min.d(‐1), 6 d.wk(‐1))
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no change in activity)
Number of subjects: 102
Study: 16724119

Group type: EXPERIMENTAL
Intervention: Vapotherm
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-flow
Number of subjects: 30
Study: 14579049

Group type: EXPERIMENTAL
Intervention: Patients with non-fatal reinfarction
Number of subjects: 2109

Group type: COMPARATOR
Intervention: Patients without non-fatal reinfarction
Number of subjects: 2109
Study: 10943584

Group type: EXPERIMENTAL
Intervention: Cloricromene (100 mg orally b.i.d.) for 6 months
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 159
Study: 8606715

Group type: EXPERIMENTAL
Intervention: Normothermia group (additional warming)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hypothermia group (routine intraoperative thermal care)
Number of subjects: 200
Study: 1573344

Group type: EXPERIMENTAL
Intervention: Active (nonpractitioner‐assisted) movement of the head to end range
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive (practitioner‐assisted) movement of the head to end range
Number of subjects: 0
Study: 3881086

Group type: EXPERIMENTAL
Intervention: Bestatin
Number of subjects: 0
Study: 30357610

Group type: EXPERIMENTAL
Intervention: Azithromycin eyedrops (2.5 mL/25 mg)
Number of subjects: 42
Study: 30273332

Group type: EXPERIMENTAL
Intervention: Inactivated whole cell pneumococcal vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26259517

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 127
Study: 25012429

Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg daily for 12 weeks
Number of subjects: 45
Study: 21603867

Group type: EXPERIMENTAL
Intervention: THERACURMIN 150 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: THERACURMIN 210 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 6
Study: 19583742

Group type: EXPERIMENTAL
Intervention: BoNT‐A+OT
Number of subjects: 22

Group type: COMPARATOR
Intervention: OT
Number of subjects: 22
Study: 17507642

Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training
Number of subjects: 146

Group type: COMPARATOR
Intervention: Overground mobility training
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Functional Independence Measure (FIM)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 50‐foot walking speed (50FW‐S)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 6‐minute walking distance (6MW‐D)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Lower Extremity Motor Score (LEMS)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Berg Balance Scale (BBS)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: WISCI
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: FIM locomotor score (LFIM)
Number of subjects: 146
Study: 12583647

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study: 11059637

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500
Study: 8729667

Group type: EXPERIMENTAL
Intervention: Surgical procedures (various types)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (30 healthy volunteers)
Number of subjects: 149
Study: 1362888

Group type: EXPERIMENTAL
Intervention: Yohimbine (4 mg three times daily for 3 weeks)
Number of subjects: 0
Study: 6147077

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (beta-blockers and diuretics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low diuretic doses
Number of subjects: 0
Study: 30425105

Group type: EXPERIMENTAL
Intervention: anti-CTLA4
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: anti-PD1
Number of subjects: 80
Study: 28404841

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg daily for 6 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25666856

Group type: EXPERIMENTAL
Intervention: Wireless pedometer with cash incentives
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Wireless pedometer with donations to charity incentives
Number of subjects: 800

Group type: COMPARATOR
Intervention: Wireless pedometer without incentives
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (no pedometer)
Number of subjects: 800
Study: 24011740

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT)
Number of subjects: 2029

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 2029
Study: 21383276

Group type: EXPERIMENTAL
Intervention: IMI plus FCU
Number of subjects: 125

Group type: COMPARATOR
Intervention: IMI only
Number of subjects: 125
Study: 19289623

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d) plus best supportive care (BSC)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d) plus best supportive care (BSC) in EGFR FISH-positive patients
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC) in EGFR FISH-positive patients
Number of subjects: 201
Study: 17239712

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 20536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20536

Group type: EXPERIMENTAL
Intervention: N-BNP levels
Number of subjects: 20536
Study: 15059444

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV) in supine position
Number of subjects: 43

Group type: COMPARATOR
Intervention: Mechanical ventilation (MV) in semi-reclining position
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intra-gastric colonization
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: sIgA content in BALF in VAP patients
Number of subjects: 43
Study: 11168029

Group type: EXPERIMENTAL
Intervention: Weekly oral azithromycin, 500 mg (n = 362)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: 1.2 MU benzathine penicillin G, intramuscularly once (n = 374)
Number of subjects: 1108

Group type: COMPARATOR
Intervention: No chemoprophylaxis (n = 372)
Number of subjects: 1108
Study: 9132031

Group type: EXPERIMENTAL
Intervention: Automatic tru-cut technique
Number of subjects: 143

Group type: COMPARATOR
Intervention: Menghini needle
Number of subjects: 143
Study: 1454357

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Chemo‐ and/or radiotherapy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: VPB and X‐ray treatment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Second line combined treatment modalities
Number of subjects: 129
Study: 6201211

Group type: EXPERIMENTAL
Intervention: Consolidation regimen A: continuous infusion of 5-azacytidine, 150 mg/sq m/day for 5 days
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Consolidation regimen B: 5-azacytidine plus beta-deoxythioguanosine, 300 mg/sq m/day for 5 days
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Consolidation regimen C: cytosine arabinoside, 100 mg/sq m/day intravenously, thioguanine, 100 mg/sq m orally every 12 hr, plus daunorubicin, 10 mg/sq m every 24 hr daily for 5 days
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Maintenance regimen D: chemotherapy, 5-day infusion of cytosine arabinoside and 2 days of daunorubicin (same doses as induction) given every 13 wk for 1 yr
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Maintenance regimen E: BCG given twice weekly for 1 mo and then monthly for 1 yr
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Maintenance regimen F: combination of regimens D and E
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Maintenance regimen D
Number of subjects: 508

Group type: COMPARATOR
Intervention: Immunotherapy (not specified)
Number of subjects: 508
Study: 29373113

Group type: EXPERIMENTAL
Intervention: 1MHz Continuous Ultrasound (CUT; 0.4W/cm2SATA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1MHz Pulsed Ultrasound (PUT; 20% duty cycle, 0.08W/cm2SATA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3MHz Continuous Ultrasound (CUT; 0.4W/cm2SATA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3MHz Pulsed Ultrasound (PUT; 20% duty cycle, 0.08W/cm2SATA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (equipment off)
Number of subjects: 30
Study: 27590460

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2‐1.5 μg/kg/h)
Number of subjects: 61
Study: 24617350

Group type: EXPERIMENTAL
Intervention: Go Sun Smart program (dissemination strategy-enhanced)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Go Sun Smart program (basic dissemination strategy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High message exposure (at least 6 Go Sun Smart materials in guest-only areas and 9 materials throughout the area)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low message exposure
Number of subjects: 0
Study: 22148972

Group type: EXPERIMENTAL
Intervention: Intrathecal combination of cisplatin and OK‐432 with hyperthermotherapy (Group A)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Intrathecal combination of cisplatin and OK‐432 without hyperthermotherapy (Group B)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 358

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 358
Study: 20686900

Group type: EXPERIMENTAL
Intervention: Vibration + Exercise (VX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise (X)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vibration (V)
Number of subjects: 20
Study: 18235115

Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg/d) in mild liver dysfunction group
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Imatinib (300 mg/d) in moderate and severe liver dysfunction groups
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Imatinib (various doses) across all liver dysfunction groups
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Imatinib (500 mg/d) in mild liver dysfunction group
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Imatinib (not specified) in moderate and severe liver dysfunction groups
Number of subjects: 89
Study: 16038686

Group type: EXPERIMENTAL
Intervention: 400 microg total dose group (four-100 microg injections over eight weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2000 microg total dose group (five-400 microg vaccinations over twelve weeks)
Number of subjects: 18
Study: 12521655

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (30 microg ethynyl estradiol and 150 microg levonorgestrel)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nonhormonal contraceptive or none (control group)
Number of subjects: 41
Study: 10910478

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Propofol plus N2O
Number of subjects: 1490
Study: 9279980

Group type: COMPARATOR
Intervention: PROG alone (200 mg PROG twice a day for 3 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PROG and ATQ (200 mg PROG and 500 mg ATQ twice a day for 3 days)
Number of subjects: 16
Study: 1998791

Group type: EXPERIMENTAL
Intervention: Alutard SQ (grass pollen extract)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30948286

Group type: EXPERIMENTAL
Intervention: Group psychological intervention with five sessions incorporating behavioural strategies facilitated by non-specialists
Number of subjects: 612

Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 612
Study: 28092065

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg preoperatively followed by five 200 mg doses every 12 hours)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no anti-inflammatory agents)
Number of subjects: 32
Study: 25812826

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy for Adolescents (PE-A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Client-Centered Therapy (CCT)
Number of subjects: 61
Study: 23103551

Group type: EXPERIMENTAL
Intervention: Rotigotine treatment (up to 3 mg/24 h after an 8-week titration phase)
Number of subjects: 185
Study: 21429448

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 26
Study: 19669675

Group type: EXPERIMENTAL
Intervention: Brief simulation of auditory hallucinations (listening condition 1: sitting in a research lab)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Brief simulation of auditory hallucinations (listening condition 2: ambulating around a college campus)
Number of subjects: 127
Study: 17696615

Group type: EXPERIMENTAL
Intervention: Primary stent implantation (n=51)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Balloon angioplasty with optional stenting (n=53)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Stented patients (n=68)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Balloon angioplasty (n=36)
Number of subjects: 104
Study: 16400895

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 6 weeks
Number of subjects: 1992
Study: 12515103

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (60 mg)
Number of subjects: 185
Study: 9704814

Group type: EXPERIMENTAL
Intervention: Mircette/placebo (150 microg desogestrel and 20 microg ethinyl estradiol for 21 days followed by placebo for 7 days)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Mircette/ethinyl estradiol (150 microg desogestrel and 20 microg ethinyl estradiol for 21 days followed by 2 days placebo and 10 microg ethinyl estradiol for 5 days)
Number of subjects: 47
Study: 7897460

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study: 2650729

Group type: EXPERIMENTAL
Intervention: 10 ml (75 mg) bupivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15 ml (112.5 mg) bupivacaine
Number of subjects: 30
Study: 334218

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31089425

Group type: EXPERIMENTAL
Intervention: VIG (70% VO2peak‐reserve)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: MOD (50% VO2peak‐reserve)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: BIKE
Number of subjects: 130

Group type: COMPARATOR
Intervention: CON (habitual lifestyle)
Number of subjects: 130
Study: 28654361

Group type: EXPERIMENTAL
Intervention: Spatial attention training using a computerized mobile training application for 5 hours over 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active placebo computerized training (control group)
Number of subjects: 0
Study: 24711165

Group type: EXPERIMENTAL
Intervention: SpinoMed®
Number of subjects: 51

Group type: COMPARATOR
Intervention: Soft lumbar orthosis (control group)
Number of subjects: 51
Study: 22948416

Group type: EXPERIMENTAL
Intervention: Atorvastatin plus diet therapy
Number of subjects: 334

Group type: COMPARATOR
Intervention: Diet therapy alone
Number of subjects: 334
Study: 21223542

Group type: EXPERIMENTAL
Intervention: Neramexane 50 mg/day
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Neramexane 75 mg/day
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Neramexane 25 mg/day
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 19336812

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial bursectomy alone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Debridement of the subacromial bursa followed by acromioplasty
Number of subjects: 57
Study: 16987766

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mucous membrane grafting
Number of subjects: 20
Study: 12700707

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11197651

Group type: EXPERIMENTAL
Intervention: EHF therapy (group 1)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Laser therapy (group 2)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Combination of laser with EHF‐puncture (group 3)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional physiotherapy (group 4, control)
Number of subjects: 137
Study: 9120155

Group type: EXPERIMENTAL
Intervention: 6 mmol of magnesium/12 mmol of potassium-DL-hydrogenaspartate daily
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 12959290

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Eating (standard 3100 kJ cold meal)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3475429

Group type: COMPARATOR
Intervention: Normal diet (A, 55 subjects)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: High-potassium diet (B, 52 subjects receiving greater than 100 mmol K+/day)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Reduced-sodium diet (C, 52 subjects receiving 50‐75 mmol Na+/day)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: High-potassium and low-sodium diet (D, 53 subjects receiving same Na+ and K+ as groups B and C)
Number of subjects: 212
Study: 30106214

Group type: EXPERIMENTAL
Intervention: Ceased pacing (CeP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continued pacing (CoP)
Number of subjects: 21
Study: 27171827

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 8 to 10 cm H2O
Number of subjects: 33

Group type: COMPARATOR
Intervention: Atmospheric pressure (Control)
Number of subjects: 33
Study: 25590292

Group type: EXPERIMENTAL
Intervention: Simultaneous exercise and psychotherapy (STEP) group (n = 26)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Individual psychotherapy (TALK group) (n = 26)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard therapy (Control group) (n = 26)
Number of subjects: 78
Study: 22380920

Group type: EXPERIMENTAL
Intervention: Vocational Enablement Protocol (VEP)
Number of subjects: 160
Study: 20381924

Group type: EXPERIMENTAL
Intervention: Intervention by a peer (patient on antiretroviral therapy)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intervention by a health professional
Number of subjects: 240

Group type: COMPARATOR
Intervention: Patients receiving a drug combination including a protease inhibitor
Number of subjects: 240

Group type: COMPARATOR
Intervention: Patients with psychological distress
Number of subjects: 240

Group type: COMPARATOR
Intervention: Patients with a higher score on the physical quality of life index
Number of subjects: 240
Study: 18753118

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir capsules (once or twice daily) with tenofovir DF and emtricitabine (both once daily) for 96 weeks
Number of subjects: 190
Study: 16120556

Group type: EXPERIMENTAL
Intervention: Children with spastic diplegia
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 12192262

Group type: EXPERIMENTAL
Intervention: Selective cyclo-oxygenase inhibitors (COX-II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucosamine, diacerein, and hyaluronan
Number of subjects: 0